Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 10, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 670,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,429.29 pence per share.
- Treasury Holdings: 293,572,678 shares (representing 5% of total issued share capital).
- Shares in Issue: 5,726,085,927 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 670,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 293,572,678. The filing does not provide comparative data for prior periods regarding financial performance.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 670,000 share repurchase based on the stated price of 1,429.29 pence.
- Confirm the updated total issued share capital to validate the 5% Treasury holding ratio.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) calculations.
- Review the company's remaining authorization for future share repurchases under the May 2006 mandate.